Table 2.
Laboratory findings in 4297 patients admitted to hospital with coronavirus disease 2019 (covid-19) who received prophylactic anticoagulation within 24 hours of hospital admission, before and after weighting
| Laboratory findings | Unweighted | IPT weighted* | |||||
|---|---|---|---|---|---|---|---|
| No anticoagulation (n=670) | Prophylactic anticoagulation (n=3627) | SMD | No anticoagulation (n=2141) | Prophylactic anticoagulation (n=2156) | SMD | ||
| Alanine aminotransferase (U/L): | |||||||
| ≤30 | 297 (44.3) | 1722 (47.5) | 0.06 | 1081 (50.5) | 1014 (47.0) | 0.07 | |
| >30 | 241 (36.0) | 1456 (40.1) | 0.09 | 751 (35.1) | 847 (39.3) | 0.09 | |
| Missing | 132 (19.7) | 449 (12.4) | 0.20 | 310 (14.5) | 295 (13.7) | 0.02 | |
| Aspartate aminotransferase (U/L): | |||||||
| ≤30 | 225 (33.6) | 1171 (32.3) | 0.03 | 717 (33.5) | 701 (32.5) | 0.02 | |
| >30 | 301 (44.9) | 1949 (53.7) | 0.18 | 1056 (49.3) | 1124 (52.1) | 0.06 | |
| Missing | 144 (21.5) | 507 (14.0) | 0.20 | 367 (17.2) | 330 (15.3) | 0.05 | |
| eGFR (mL/min/1.73 m2): | |||||||
| ≥60 | 354 (52.8) | 2034 (56.1) | 0.07 | 1164 (54.4) | 1196 (55.5) | 0.02 | |
| 30-59 | 159 (23.7) | 957 (26.4) | 0.06 | 555 (25.9) | 559 (25.9) | 0.00 | |
| <30 | 82 (12.2) | 418 (11.5) | 0.02 | 274 (12.8) | 252 (11.7) | 0.03 | |
| Missing | 75 (11.2) | 218 (6.0) | 0.19 | 147 (6.9) | 149 (6.9) | 0.00 | |
| Glucose (mmol/L): | |||||||
| ≤9.44 | 486 (72.5) | 2766 (76.3) | 0.09 | 1636 (76.4) | 1628 (75.5) | 0.02 | |
| >9.44 | 135 (20.1) | 759 (20.9) | 0.02 | 426 (19.9) | 449 (20.8) | 0.02 | |
| Missing | 49 (7.3) | 102 (2.8) | 0.21 | 79 (3.7) | 78 (3.6) | 0.00 | |
| Hemoglobin (g/L): | |||||||
| ≤140 | 387 (57.8) | 2151 (59.3) | 0.03 | 1248 (58.3) | 1276 (59.2) | 0.02 | |
| >140 | 231 (34.5) | 1353 (37.3) | 0.06 | 812 (37.9) | 792 (36.7) | 0.02 | |
| Missing | 52 (7.8) | 123 (3.4) | 0.19 | 81 (3.8) | 88 (4.1) | 0.02 | |
| Platelet count (×109/L): | |||||||
| ≤230 | 421 (62.8) | 2433 (67.1) | 0.09 | 1472 (68.8) | 1430 (66.3) | 0.05 | |
| >230 | 195 (29.1) | 1097 (30.2) | 0.02 | 594 (27.7) | 647 (30.0) | 0.05 | |
| Missing | 54 (8.1) | 97 (2.7) | 0.24 | 75 (3.5) | 78 (3.6) | 0.01 | |
| White blood cell count (×109/L): | |||||||
| ≤6 | 299 (44.6) | 1747 (48.2) | 0.07 | 1038 (48.5) | 1025 (47.6) | 0.02 | |
| >6 | 319 (47.6) | 1786 (49.2) | 0.03 | 1031 (48.2) | 1054 (48.9) | 0.02 | |
| Missing | 52 (7.8) | 94 (2.6) | 0.24 | 72 (3.4) | 76 (3.5) | 0.01 | |
| Lymphocyte count (×109/L): | |||||||
| ≤0.6 | 100 (14.9) | 600 (16.5) | 0.04 | 353 (16.5) | 352 (16.3) | 0.01 | |
| >0.6 | 431 (64.3) | 2523 (69.6) | 0.11 | 1428 (66.7) | 1479 (68.6) | 0.04 | |
| Missing | 139 (20.7) | 504 (13.9) | 0.18 | 359 (16.8) | 326 (15.1) | 0.05 | |
| Total cholesterol (mmol/L): | |||||||
| ≤3.37 | 152 (22.7) | 678 (18.7) | 0.10 | 398 (18.6) | 414 (19.2) | 0.02 | |
| >3.37 | 415 (61.9) | 2444 (67.4) | 0.11 | 1410 (65.9) | 1435 (66.6) | 0.01 | |
| Missing | 103 (15.4) | 505 (13.9) | 0.04 | 333 (15.6) | 307 (14.2) | 0.04 | |
| HDL cholesterol (mmol/L): | |||||||
| <0.98 | 180 (26.9) | 917 (25.3) | 0.04 | 551 (25.7) | 548 (25.4) | 0.01 | |
| 0.98-1.28 | 202 (30.1) | 1213 (33.4) | 0.07 | 719 (33.6) | 710 (33.0) | 0.01 | |
| ≥1.29 | 181 (27.0) | 988 (27.2) | 0.01 | 535 (25.0) | 587 (27.2) | 0.05 | |
| Missing | 107 (16.0) | 509 (14.0) | 0.05 | 337 (15.7) | 311 (14.4) | 0.04 | |
| Triglycerides (mmol/L): | |||||||
| <1.55 | 58 (8.7) | 310 (8.5) | 0.00 | 175 (8.2) | 183 (8.5) | 0.01 | |
| 1.55-2.32 | 133 (19.9) | 628 (17.3) | 0.07 | 362 (16.9) | 385 (17.9) | 0.02 | |
| ≥2.33 | 370 (55.2) | 2165 (59.7) | 0.09 | 1259 (58.8) | 1268 (58.8) | 0.00 | |
| Missing | 109 (16.3) | 524 (14.4) | 0.05 | 344 (16.1) | 319 (14.8) | 0.03 | |
IPT=inverse probability of treatment; SMD=absolute value of the standardized mean difference; eGFR=estimated glomerular filtration rate; HDL=high density lipoprotein.
*
Counts after IPT weighting were calculated by multiplying weights by constant factor k, where k was the ratio of observed sample size to number in the pseudopopulation after weighting; in this study, k=4297/8576.